Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
First, the bad news. You have been diagnosed with non-small cell lung cancer (NSCLC). The good news is that it is “early stage” meaning you have a reasonable chance of achieving a cure. The devil is in the details of how to achieve a cure…
I don’t mean to sound cynical but just because your surgeon says “we got it all!” after your radical resection does NOT mean that you might not relapse. Five year survival statistics for early stage NSCLC, quoted below, of less than 50% means that more than half of all early stage NSCLC patients don’t live for five years after their diagnosis.
My experience living with incurable cancer since my diagnosis in early 1994 has taught me that while standard-of-care therapy like surgery for NSCLC patients is a great first step, it is only a first step.
As the study linked and excerpted below explains, adjuvant chemotherapy can add to both overall and disease-free survival (OS and DFS). But there are many other non-conventional therapies that you may not know about.
First and foremost, if you smoke, stopping smoking has a large survival benefit. Further, research shows that there are integrative therapies that is both cytotoxic to lung cancer and synergize with certain types of chemotherapy. Nutrition, lifestyle, detoxification, supplementation, C-B-D oil and other evidence-based, non-toxic, non-conventional therapies all can help you beat the average five year survival statistics and get to a cure.
To learn more about evidence-based therapies for lung cancer, please watch the short video below:
Have you been diagnosed with NSCLC? What stage? What therapies are you considering? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Postoperative adjuvant chemotherapy without radiotherapy improves survival of patients with stage I-II, I, and IB non-small cell lung cancer (NSCLC), but not for those with IA disease, a study published in the journal OncoTargets and Therapy has shown.
According to the American Cancer Society, the 5-year observed survival rates, which were calculated from the National Cancer Institute’s SEER database, for patients with stage IA, IB, IIA, and IIB NSCLC are 49%, 45%, 30%, and 31%, respectively.
For the meta-analysis, researchers at Zhongnan Hospital of Wuhan University in China sought to evaluate the effectiveness of postoperative chemotherapy without radiotherapy in patients with early stage NSCLC. Researchers analyzed data from 14 trials that included 3,923 patients with histologically confirmed stage I and/or II NSCLC who underwent radical resection and received surgery followed by chemotherapy or surgery alone.
Results showed that postoperative chemotherapy significantly improved disease-free survival and overall survival compared with surgery alone. Subgroup analyses demonstrated that postoperative chemotherapy was not beneficial in patients with stage IA disease, but there was a trend toward supporting the use of adjuvant chemotherapy…
Conclusion: This meta-analysis demonstrates that postoperative chemotherapy without radiotherapy improves survival of stage I–II, I, and IB non-small cell lung cancer patients, but not for IA. Meanwhile, efficacy of cisplatin-based chemotherapy is comparable to single UFT in OS, but better in DFS, which should be paid more attention in future clinical practice.”
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
I consult the independent evaluation service Consumerlab.com frequently. For one low annual payment, I can read about and evaluate all of the nutritional supplement that I take.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”